Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

19.16 USD -0.25 (-1.29%)
Official Closing Price Updated: 7:57 PM EST, Nov 30, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,247,600
Open 19.63
Bid (Size) 19.17 (1)
Ask (Size) 19.24 (18)
Prev. Close 19.41
Today's Range 18.76 - 20.10
52wk Range 13.67 - 27.80
Shares Outstanding 296,866,380
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of CABOMETYX®... 
From Business Wire News Releases
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in December
Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following virtual investor conferences in December: 
From Business Wire News Releases

Performance

YTD
+8.49%
+8.49%
1 Month
-7.04%
-7.04%
3 Month
-13.77%
-13.77%
6 Month
-20.63%
-20.63%
1 Year
+14.73%
+14.73%

More News

Read More
Exelixis Announces Third Quarter 2020 Financial Results and Provides Corporate Update
From Business Wire News Releases
Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
From Business Wire News Releases
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November
From Business Wire News Releases
EQAL's Holdings Imply 11% Gain Potential
Tags ETFs
From ETF Channel
Exelixis Announces Takeda and Ono Submit Supplemental Application for CABOMETYX® (cabozantinib) in Combination with OPDIVO® (nivolumab) for the Treatment of Unresectable, Advanced or Metastatic Renal
From Business Wire News Releases
12 Healthcare Stocks Moving In Thursday's After-Market Session
Tags Health Care CHRS After/Hours Center
From Benzinga
Exelixis Announces First Patient Enrolled in Phase 1 Trial Cohort Evaluating XL092 in Combination with Atezolizumab in Patients with Advanced Solid Tumors
From Business Wire News Releases
Got $50? 4 Smart Stocks to Buy Into Right Now
Tags EXEL JUSHF SIRI
From Motley Fool
Exelixis to Release Third Quarter 2020 Financial Results on Thursday, November 5, 2020
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.